Triple negative breast cancer (TNBC) is defined based on the lack of the expression of the estrogen (ERα) and progesterone (PR) receptors, as well as the absence of HER2 amplification. As this is a diagnosis of exclusion, TNBC is a highly heterogeneous subgroup of breast cancer with poor outcome. While numerous studies have aimed to further stratify TNBC in order to tailor treatment (reviewed in Bianchini and colleagues)¹, to date these have not resulted in a change in standard of care (SoC); most patients receive DNA-damaging chemotherapy ± taxanes in the adjuvant and, more recently, the neo-adjuvant setting.^2,3 While some patients respond very well to this treatment regimen, there is still a significant proportion of patients who receive little clinical benefit, relapse and die from their disease in a short period of time.⁴ Therefore, there is a significant unmet clinical need to identify biomarkers that allow TNBC to be stratified based on knowledge of the underlying biology and for treatment options to be tailored accordingly.

中文翻译：

---

Pin1 在三阴性乳腺癌的治疗反应和临床结果中起关键作用

三阴性乳腺癌 (TNBC) 的定义是基于缺乏雌激素 (ERα) 和孕激素 (PR) 受体的表达，以及 HER2 扩增的缺失。由于这是一种排除性诊断，因此 TNBC 是乳腺癌的高度异质性亚组，结果较差。尽管许多研究旨在进一步对 TNBC 进行分层以定制治疗方案（在 Bianchini 及其同事中进行了审查）¹，但迄今为止，这些研究并未导致护理标准 (SoC) 发生变化；大多数患者在辅助和最近的新辅助环境中接受破坏 DNA 的化疗±紫杉烷类。^2,3虽然一些患者对这种治疗方案反应非常好，但仍有很大一部分患者几乎没有临床获益，会在短时间内复发并死于疾病。⁴因此，在识别生物标志物方面存在显着未满足的临床需求，这些生物标志物允许根据基础生物学知识对 TNBC 进行分层，并相应地调整治疗方案。